1887

oa SA Pharmaceutical Journal - Galvus® (vildagliptin) : South Africa's first DPP-4 inhibitor : new product focus : drug info

 

Abstract

Galvus® (vildagliptin) is a new oral antidiabetic agent indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus. Vildagliptin is approved for use as add-on therapy in patients taking metformin, a sulphonylurea or insulin.

Loading

Article metrics loading...

/content/mp_sapj/78/3/EJC82556
2011-04-01
2016-12-09
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error